Internal Medicine, Department of Clinical and Biological Sciences at San Luigi Hospital, University of Turin, Orbassano, Turin, Italy.
Pathology, Department of Oncology at San Luigi Hospital, University of Turin, Orbassano, Turin, Italy.
PLoS One. 2018 May 7;13(5):e0196931. doi: 10.1371/journal.pone.0196931. eCollection 2018.
Mitotane is the reference drug for adrenocortical carcinoma (ACC) and the metabolic activation of the drug is considered as essential for its activity. The aim of this study was to assess the role of CYP11B1 on mitotane action and metabolism in H295R ACC cells to understand whether this enzyme may influence mitotane action. The simultaneous incubation with mitotane and metyrapone, an adrenolytic molecule targeting 11-beta-hydroxylase, did not influence mitotane-mediated cytotoxic effect and metabolism in H295R ACC cells. CYP11B1 silencing confirmed the lack of a significant metyrapone effect on mitotane action. The present findings do not support the view that CYP11B1 catalyzes a crucial step in the metabolic activation of mitotane and that CYP11B1 confers the adrenal specificity to mitotane.
美替拉酮是治疗肾上腺皮质癌(ACC)的参考药物,药物的代谢激活被认为是其活性所必需的。本研究旨在评估 CYP11B1 在 H295R ACC 细胞中美替拉酮作用和代谢中的作用,以了解该酶是否会影响美替拉酮的作用。同时孵育美替拉酮和米托坦,一种针对 11-β-羟化酶的肾上腺溶解分子,并不影响 H295R ACC 细胞中美替拉酮介导的细胞毒性作用和代谢。CYP11B1 沉默证实米托坦对美替拉酮作用没有显著影响。目前的研究结果不支持 CYP11B1 催化美替拉酮代谢激活的关键步骤的观点,也不支持 CYP11B1 赋予美替拉酮肾上腺特异性的观点。